Dawson James Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $3
Portfolio Pulse from Benzinga Newsdesk
Dawson James analyst Jason Kolbert initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and a price target of $3.

February 28, 2024 | 7:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dawson James analyst Jason Kolbert has initiated coverage on Tonix Pharmaceuticals with a Buy rating and set a price target of $3.
The initiation of coverage by a reputable analyst with a Buy rating and a specific price target usually indicates a positive outlook on the stock, suggesting potential upside. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100